MedTrace Logo

COAgulation Disorders in Ischaemic and Haemorrhagic Stroke

NCT05974111 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-11-14

No results posted yet for this study

Summary

In this study the investigators will assess both procoagulant and anticoagulant pathways using thrombin generation and platelet function tests; as well as neuronal ischemia using cell free DNA in all patients presenting with ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further investigated. As such the investigators aim to characterise the patient's coagulation profile before administration of any treatment. By assessing these pathways the investigators strive to detect specific markers to predict vital and functional outcome at 3 months in these patients. Finally the investigators may provide new pathophysiological insights in the course of disease following these events that can possibly improve future therapeutic strategies.

Conditions

Interventions

DIAGNOSTIC_TEST

blood sampling

At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation

Sponsors & Collaborators

  • Synapse bv

    collaborator INDUSTRY

  • Ziekenhuis Oost-Limburg

    lead OTHER

Principal Investigators

  • Hendrik Stragier, MD · Ziekenhuis Oost-Limburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2025-05-02
Completion
2025-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05974111 on ClinicalTrials.gov